603108 Shanghai Runda Medical Technology
- 18.16
- -1.04-5.42%
Shanghai Runda Medical Technology News
Runda Healthcare (603108.SH): Net profit in 2023 fell by 34.58% to 273 million yuan, and plans to pay 10 to 1 yuan
On April 27, Ge Longhui (603108.SH) released its 2023 annual report. During the reporting period, the company's overall revenue and profit declined due to external macroeconomic environment and medical policies. Overall, total revenue and profit declined. Overall, total revenue of 9.147 billion yuan, down 12.84% from the same period last year, achieved net profit attributable to shareholders of listed companies of 273 million yuan, a decrease of 34.58% over the same period last year. It is proposed to distribute a cash dividend of 1 yuan (tax included) for every 10 shares to all shareholders.
Runda Healthcare (603108.SH): Net profit of 22.6038 million yuan in the first quarter decreased by 72.11% year-on-year
On April 27, Ge Longhui (603108.SH) released its report for the first quarter of 2024, achieving operating income of 2,072 billion yuan, a year-on-year decrease of 4.85%; net profit attributable to shareholders of listed companies of 22.6038 million yuan, a year-on-year decrease of 72.11%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 18.60.26 million yuan, a year-on-year decrease of 74.27%; and basic earnings per share of 0.04 yuan.
Runda Healthcare (603108.SH) announced first-quarter results, net profit of 22.6 million yuan, a year-on-year decrease of 72.11%
Runda Healthcare (603108.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 2,072 billion yuan, a year-on-year decrease of 4.85%; net profit to mother was 22.6 million yuan, a year-on-year decrease of 72.11%; after deducting non-net profit of 18.6 million yuan, a year-on-year decrease of 74.27%. Basic earnings per share were $0.04.
Express News | American Health released the first domestic AI robot for health management - “Health Xiaomei”
Express News | American Health signs comprehensive cooperation agreements with HUAWEI CLOUD and Runda Healthcare
Runda Healthcare (603108) Review: Joining hands with Huawei and Liuyao to commercialize 2C and 2B is expected to accelerate implementation
Runda signed a cooperation agreement with Huawei and Liu Yao: On December 9, the 2023 HUAWEI CLOUD Digital Health Innovation Summit was held in Dongguan, Guangdong, with the theme of “Health Inclusiveness and Digital Intelligence”. At the meeting, HUAWEI CLOUD and Guangxi Liuyao Group and Run
The AI medical concept is active, and the country's new health is rising and falling
Gelonghui November 13 | Guoxin Health rose and stopped, Runda Healthcare, Wanda Information, Weining Health, and Neusoft Group had the highest gains. At the 2023 World Internet Conference Wuzhen Summit, Wu Wenda, CEO of Tencent Health, explained at the World Internet Leading Scientific and Technological Achievements Launch Event that the “Tencent Digital Intelligence Medical Imaging Platform” has fully opened more than 20 medical AI engines to help scientific research and innovation, and uses “cloud+AI” to achieve various digital imaging applications such as remote diagnosis, remote consultation, and auxiliary diagnosis, and promote innovation in the entire medical AI chain.
The pharmaceutical business sector boosted, and Runda Healthcare rose nearly 7%
Gelonghui November 10 | Runda Healthcare rose nearly 7%, followed by Yixintang, SaiLi Medical, Baiyang Pharmaceutical, and Jianzhijia.
Runda Healthcare (603108) Quarterly Report Review: Third quarter performance fluctuations continue to focus on the progress of AI products
Investment points: Established in 1999, Runda Medical Technology Co., Ltd. is committed to the field of in vitro diagnostic distribution services. Its main business is to provide various medical laboratories through its own comprehensive service system (with public hospital laboratories of level 2 and above)
Runda Medical (603108) 2023 Third Quarter Report Review: 23Q3 Apparent Performance Pressures, Releases Comprehensive Smart Testing Solution
Event: The company released its 2023 three-quarter report. The first three quarters achieved revenue of 6.890 billion yuan, a year-on-year decrease of 9.74%; net profit of the mother was 283 million yuan, down 7.38% from the previous year, and net profit of 187 million yuan was deducted from the non-return mother's net profit
Runda Healthcare: Shareholder Zhu Wenyi and co-actors recently reduced their holdings by 1.72%
Glonghui, October 13 | Runda Medical announced that it received notification letters from shareholders Ms. Zhu Wenyi and Mr. Liu Hui. Shareholder Zhu Wenyi and co-actor Liu Hui reduced their holdings by a total of 1.72% from May 18, 2023 to October 13, 2023. After this change in equity, the total shareholding ratio of the company's shareholders, Ms. Zhu Wenyi and Mr. Liu Hui, changed from 13.80% to 12.08%.
Runda Healthcare (603108.SH): Xiaohui, a large model jointly developed and launched with HUAWEI CLOUD, is currently in closed beta in the early stages of official commercialization
Glonghui, Oct. 11, 丨 Runda Healthcare (603108.SH) announced that regarding the company's cooperation with HUAWEI CLOUD (HUAWEI CLOUD for short), there is commercial cooperation between the company and HUAWEI Cloud Computing Technology Co., Ltd. (HUAWEI CLOUD for short). Xiaohui, a big model jointly developed and launched by the two parties, is currently in closed beta in the early stages of formal commercialization. There is no signed customer yet, and there is uncertainty about subsequent customer development and contracts.
The pharmaceutical business directly boosted Runda Medical's rise and stop
Glonghui, Oct. 11 | Runda Medical's closing price went up and down, with Kaikai Industrial, Celi Healthcare, Dajiaweikang, and Hefu China following suit.
Dragon Tiger list丨Runda Medical rose and stopped, Tianfeng Securities Shenzhen Branch made a net purchase of 141 million yuan
Runda Healthcare (603108.SH) rose and stopped today, with a turnover rate of 12.25% and a turnover of 1.05 billion yuan. According to data from the Dragon Tiger List, the Shenzhen branch of Tianfeng Securities bought one seat, with a net purchase of 141 million yuan; Shanghai Stock Connect bought 52.2724 million yuan and sold 26.930,800 yuan at the same time, with a net purchase of 253.416 million yuan; one institution sold two seats, with a net sale of 26.404 million yuan.
Runda Healthcare (603108) Interim Report Review: Focus on the Progress of AI Products
Investment points: Established in 1999, Runda Medical Technology Co., Ltd. is committed to the field of in vitro diagnostic distribution services. Its main business is to provide various medical laboratories through its own comprehensive service system (with public hospital laboratories of level 2 and above)
Runda Healthcare (603108.SH): Currently, the depression detection products developed by the company are still in the development stage
GLONGHUI September 12丨Some investors asked Runda Healthcare (603108.SH): Business progress in the area of depression? I heard that it is possible to cooperate with education-related departments? Runda Medical Reply: Dear Investors! Currently, the depression testing products developed by the company are still in the development stage. Please pay attention to the information published on the company's official channels for related developments. Thank you for your interest.
Runda Healthcare (603108.SH): The company is committed to building a healthcare model with innovative thinking and humane care
GLONGHUI September 12丨Some investors asked Runda Healthcare (603108.SH): What are the advantages of the company making a big medical AI model? How much training data has been formed? Why did Huawei choose corporate cooperation? Thank you. Runda Medical Reply: Dear Investors! Based on the company's rich experience and achievements in the field of smart healthcare, combined with HUAWEI CLOUD's leading computing power and hardware advantages, the company is committed to building a healthcare model with innovative thinking and human care. Thank you for your interest.
Runda Healthcare (603108.SH): The company will continue to focus on its main business and steadily advance development
GLONGHUI, September 12丨Some investors asked Runda Healthcare (603108.SH) a question: Does the company have formed huge data assets that have been cleaned and desensitized belong to the company? Can it be commercialized? Thank you. Runda Medical Reply: Dear investors, the company will continue to focus on its main business and steadily advance development. Thank you for your suggestions and attention.
Runda Healthcare (603108.SH): An inclusive AI medical model product developed based on the Huijian product development foundation combined with Huawei's Pangu model technology will soon be officially released
GLONGHUI, September 12丨An investor asked Runda Healthcare (603108.SH): How many hospitals are already operating on the B-side of the medical AI model developed by the company based on the Huawei Pangu model? How effective is the operation? How many medical institutions are currently being discussed or followed? How many companies do you plan to expand to this year and next two years? Thank you. Runda Medical Reply: Dear Investors! At present, the Huijian products developed by the company have been promoted and used by more than 40 medical institutions in China, and have received good reviews and recognition from users. An inclusive AI medical model product developed based on the product development foundation of Huijian combined with Huawei's Pangu model technology
Runda Healthcare (603108): Steady growth in performance in the first half of the year is optimistic about the prospects of the company's AI model
The company released its semi-annual report for 2023: during the reporting period, the company achieved operating income of 4.521 billion yuan, a year-on-year decrease of 5.0%; achieved net profit of 175 million yuan, an increase of 9.7% over the previous year; achieved net profit of 1.5 billion yuan without return to parent
Analysis
Price Target
No Data
